Share |

vaccine

The venture capital firm investing where IT and Biology meet

April 22, 2022

Joey Mason and Ed Snow, the founders of Duplex Capital Partners, talk about how their firm enables personalised therapeutics through data-driven technology and leading-edge medical techniques.

Coming from entrepreneurial healthcare and venture capital company growth backgrounds respectively, Joey Mason and Ed Snow know the pitfalls and opportunities that come from investing in healthcare.

Their firm Duplex Capital Partners aims to profit from investing in “Digitally-based life science technology companies innovating to underpin the next generation of biotechnology products.” Here, they explain what they do and where they think the industry is going.

Philanthropy versus impact investing in the world of the wealthy

January 17, 2022

Throughout the pandemic, members of the ultra-wealthy community have made a monumental social impact, but just one made a financial profit. Paul Westall, co-founder of the Agreus Group, asks do family offices always need a return when it comes to giving and is it possible to have it both ways?

This is an extract from the How To Change The World Report, a guide to philanthropy and impact investing by family office recruiter, Agreus. Download the full report here.

Family offices transfer wealth, rebalance portfolios and embrace technology during Covid-19 pandemic

July 5, 2021

More families recognise the need to invest in the family capital as a means to sustain the financial capital of the family, Dr Kirby Rosplock says.

More families recognise the need to invest in the family capital as a means to sustain the financial capital of the family, Dr Kirby Rosplock says.

The family member turned recognised researcher, innovator, adviser, author and speaker in the family business and family office space tells CampdenFB about the shifts she is seeing take place in wealth management, investment strategy and technological sophistication within family offices in the wake of the Covid-19 pandemic.

Ruffer on why inflation is the ‘starting gun’ for global volatility

June 17, 2021

“I have little doubt that with excess savings, new stimulus savings, huge deficit spending, more QE, a new potential infrastructure bill, a successful vaccine and euphoria around the end of the pandemic, the US economy will likely boom,” Jamie Dimon, chief executive of JPMorgan Chase, said in May 2021.

The number of companies raising prices in the United States is at a 35-year high.

“This boom could easily run into 2023 because all the spending could extend well into 2023.”

Telecoms, vaccine and energy innovations at next funds and direct Investments webinar

March 11, 2021

Qualifying family offices and private investors will hear exclusive proposals from a sky-high telecoms vehicle, a next-gen cancer and Covid therapeutic, a sports betting platform and a low-cost tidal electricity generator, at the 9th virtual Campden Wealth Funds & Direct Investments Event on 15 April.

Each of the four investment opportunities will be introduced in 15-minute slots to all family offices and investors who will be able to ask questions and discuss the potential.

Is the tide turning for value managers?

February 15, 2021

While 2021 has started not unlike how much of 2020 played out, with Covid-19 infections continuing to spread and many countries reimplementing lockdown measures, the approval and rollout of various vaccines to combat the coronavirus has been an undeniable game-changer for markets. It's provided a clearer road map for a return to some form of normality, although the path ahead is still likely to remain bumpy, with continued uncertainties in the offing.

Ruffer Radio: A view from the bridge

January 12, 2021

The year 2020 will loom large on financial markets for many years to come. As we cautiously make our way out of the crisis, Duncan MacInnes and Fiona Ker review the more startling developments of the last year, share their insights into the ongoing recovery and look ahead to some of key challenges facing investors in 2021.

The year 2020 will loom large on financial markets for many years to come.

As we cautiously make our way out of the crisis, Duncan MacInnes and Fiona Ker, of Ruffer LLP, review the more startling developments of the last year, share their insights into the ongoing recovery and look ahead to some of key challenges facing investors in 2021.

FB Roundup: Bertelsmann, Bombardier, Walmart

December 12, 2020

Bertelsmann books Simon & Schuster for $2.175 billion, Bombardier private jet sales soar in the coronavirus age, Walmart offers to give Covid-19 vaccinations.

Bertelsmann books Simon & Schuster for $2.175 billion

German media family business Bertelsmann has acquired publishing house Simon & Schuster for $2.175 billion from the US Redstone-family-owned media company ViacomCBS.

Bertelsmann, the international media, services and education company, said it was further expanding its global content businesses in the US, its second-largest market, with the deal for the publisher of Hillary Clinton, John Irving, Stephen King and Bob Woodward.

Russell Investments' 2021 Global Market Outlook: The old normal

December 10, 2020

We believe that vaccine prospects are likely to make 2021 a year of global economic recovery. While markets have priced in a fair amount of the good news, more gains seem possible as corporate profits rebound and central banks remain on hold.

With the world in the early post-recession recovery phase of the business cycle, our medium-term outlook for economies and corporate earnings is positive. We believe that 2021 will feature an extended period of low-inflation, low-interest rate growth that favours equities over bonds.

A vaccine: To v or not to v? That is the question

September 10, 2020

Could a vaccine change market leadership? When will enough doses of FDA-approved Covid-19 vaccine(s) to inoculate 25 million people be distributed in the US? The superforecasters of the Good Judgement Project believe there is a 93% probability we will have an FDA-approved vaccine in a year, and enough of it to inoculate 25 million people in the US. This is up from just 20% in the dark days of April.